PHILADELPHIA, Sept. 3 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today the launch of the RELENZA(R) (zanamivir) Inhalation Powder Pandemic ...

RESEARCH TRIANGLE PARK, N.C., Dec. 19 /PRNewswire/ -- GlaxoSmithKline (GSK) is prepared to respond to public health needs for RELENZA(R) (zanamivir) Inhalation Powder this flu season following a ...

Glaxo Wellcome Inc. is writing to inform you of important revisions to the safety labeling for Relenza (zanamivir for inhalation), which is approved for the treatment of uncomplicated acute ...

February 29, 2008 — Many patients receiving treatment for asthma and chronic obstructive pulmonary disease (COPD) are swallowing capsules of inhalation powder rather than placing them in ...